Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Window of Opportunity Trial of durvalumab or durvalumab + tremelimumab as neoadjuvant therapy in resectable head and neck cancer
KCT0003333Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2019
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, tremelimumab in head and neck cancer (HNC), head and neck squamous cell carcinoma (HNSCC), sponsored by AstraZeneca. Started Jan 2019; status: completed.
02
Drugs
durvalumabtremelimumab
03
Conditions
head and neck cancer (HNC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on KCT0003333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003333.